0001209191-18-015100.txt : 20180301
0001209191-18-015100.hdr.sgml : 20180301
20180301171049
ACCESSION NUMBER: 0001209191-18-015100
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180227
FILED AS OF DATE: 20180301
DATE AS OF CHANGE: 20180301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Waldin Jan-Paul
CENTRAL INDEX KEY: 0001733176
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37347
FILM NUMBER: 18658788
MAIL ADDRESS:
STREET 1: 77 KING STREET WEST
STREET 2: SUITE 3000
CITY: TORONTO
STATE: A6
ZIP: M5K 1G8
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XBiotech Inc.
CENTRAL INDEX KEY: 0001626878
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8201 E. RIVERSIDE DRIVE
STREET 2: BUILDING 4, SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78744
BUSINESS PHONE: 512-386-2930
MAIL ADDRESS:
STREET 1: 8201 E. RIVERSIDE DRIVE
STREET 2: BUILDING 4, SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78744
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-27
0
0001626878
XBiotech Inc.
XBIT
0001733176
Waldin Jan-Paul
77 KING STREET WEST
SUITE 3000
TORONTO
A6
M5K 1G8
ONTARIO, CANADA
1
0
0
0
Director Stock Option
4.83
2018-02-27
4
A
0
25000
0.00
A
2018-08-27
2028-02-27
Common Stock
25000
25000
D
Upon election as a Board Member and pursuant to the Board Member Agreement in place between Jan-Paul Waldin (the "Reporting Person") and the Company (the "Agreement"), the Reporting Person was granted non-qualified stock options to purchase 25,000 shares of the Company's common stock on February 27, 2018 (the "Grant Date"). All granted options will be exercisable at a price equal to the closing price of the Company's common stock, as reported by NASDAQ, on the Grant Date, and vest in two equal installments occurring six months and 12 months following the Grant Date, subject to continued service as a Director. The Options shall expire ten years from the Grant Date, unless terminated earlier in accordance with the Plan or the Reporting Person's stock option agreement. In accordance with the Plan, the Options will remain exercisable for 90 days after the date of the Reporting Person's termination without cause or resignation.
/s/ Ashley Otero under Power of Attorney for Jan-Paul Waldin
2018-03-01